Key takeaways
- Annual GLP-1 prescriptions for children ages 8 to 11 with obesity rose 310-fold between 2019 and 2026.
- Nearly 94% of children prescribed these off-label medications had severe obesity, and over 65% had comorbidities like prediabetes or hyperlipidemia.
- Prescriptions were concentrated in socioeconomically advantaged areas, exposing deep disparities in pediatric obesity care.
- Because online telehealth providers do not treat minors, parents facing high out-of-pocket costs must navigate specialized pediatric clinics.
What happened
A new study published in Pediatrics reveals that off-label prescribing of GLP-1 weight-loss medications for children ages 8 to 11 with obesity has surged 310-fold. Researchers analyzing data from over 3.5 million children found that annual prescription rates in this age group rose from 0.03% in 2019 to 9.3% in 2026.
Why it matters
The massive clinical shift highlights how pediatricians are increasingly turning to highly effective medications like semaglutide (Wegovy) and tirzepatide (Zepbound) off-label, despite the fact that the Food and Drug Administration (FDA) has not officially approved these brand-name weight-loss drugs for children under the age of 12. For parents navigating severe childhood obesity, this clinical acceleration signal is profound. However, because insurance coverage for off-label pediatric use is incredibly rare, families face steep financial barriers.
This financial squeeze is expected to drive more parents toward the cash-pay telehealth market and compounded alternatives, mirroring the adult market where high costs lead patients to compare online options. However, this rapid rise in pediatric prescribing also introduces unique health considerations, such as the heightened gallbladder risks linked to youth GLP-1 use.
What the data says
The retrospective cross-sectional study, led by Babak J. Orandi, MD, PhD, of the NYU Grossman School of Medicine, analyzed electronic health records of 3,520,531 children with obesity from January 2019 to June 2026.
- Overall Prescriptions: While the percentage increase was massive, the absolute number of treated children remains small. Across the entire study period, only 20,282 children (0.6% of the study cohort) actually received a GLP-1 prescription.
- A "Sickest First" Approach: Doctors are not handing these drugs out casually. Nearly 94% of the children prescribed a GLP-1 had severe obesity, meaning their body mass index (BMI) was at least 120% of the 95th percentile on CDC growth charts.
- Comorbidities: Over 65% of children prescribed a GLP-1 had at least one obesity-related health issue, compared to just 19.6% of untreated children. High-risk conditions among young GLP-1 users included:
Hyperlipidemia: 36.9% Prediabetes: 25.2% Obstructive sleep apnea: 24.1% Metabolic dysfunction-associated steatotic liver disease (fatty liver): 13.8% Hypertension:* 12.8%
- Socioeconomic Disparities: The data showed that GLP-1 prescriptions were far more common among children living in areas with lower social vulnerability, suggesting that wealthy, well-insured, or cash-paying families are currently the primary beneficiaries of this clinical shift.
How it compares
Currently, the FDA has approved liraglutide (Saxenda) and semaglutide (Wegovy) for chronic weight management only in adolescents aged 12 and older. For children ages 8 to 11, any GLP-1 use is strictly off-label.
While clinical trials have evaluated semaglutide, tirzepatide, and liraglutide in children as young as 6, official pediatric approvals are lagging. In practice, semaglutide was the most common initial prescription in the study, while liraglutide was the least common.
For parents, obtaining these medications off-label is an uphill battle compared to adult access. In the adult space, patients can easily fill out an online questionnaire and obtain brand-name or compounded semaglutide through direct-to-consumer telehealth platforms. However, online GLP-1 providers generally do not treat children under 18. This means parents must rely on specialized pediatric clinics, where a brand-name Wegovy or Zepbound prescription can cost upwards of $1,000 to $1,350 per month out-of-pocket if insurance denies coverage.
How this fits the bigger picture
The study authors warned that as clinical guidelines endorse earlier intervention, the benefits of GLP-1s may "preferentially accrue to socioeconomically advantaged children," widening public health disparities.
This mirrors a broader trend across the US healthcare system. As we previously covered in our analysis of how employers are overhauling benefits due to GLP-1 costs, insurance companies and employers are rapidly tightening coverage criteria to protect their bottom lines. When commercial insurers restrict access, even for adults with clear diagnoses, it forces families to look elsewhere.
Furthermore, this is not the only clinical area experiencing a massive off-label surge. We have recently seen a similar trend in dermatology, where doctors are increasingly prescribing GLP-1s off-label for inflammatory skin conditions. Whether it is an adult seeking alternative benefits or a parent trying to help a child with severe metabolic disease, the lack of traditional insurance coverage is driving a massive, consumer-led movement toward cash-pay healthcare solutions.
What happens next
Looking forward, clinical trials investigating next-generation GLP-1 and dual-agonist therapies in pediatric cohorts are ongoing. Manufacturers like Novo Nordisk and Eli Lilly are actively working to secure formal FDA approvals for the 6-to-11 age bracket, which would represent a massive step toward securing insurance coverage.
Until official FDA pediatric labels are expanded, medical societies and health policymakers face the challenge of establishing equitable access pathways. For now, pediatricians will likely continue to reserve these powerful off-label treatments for the children at the absolute highest risk for immediate cardiovascular and metabolic disease.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified pediatrician or specialist before starting any medication or weight-loss treatment for your child.